Your browser doesn't support javascript.
loading
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Huang, Jiwei; Su, Ruopeng; Chen, Zeyu; Jiang, Shuai; Chen, Minfeng; Yuan, Yichu; Hu, Hailong; Fu, Changde; Huang, Zhiyang; Wang, Zhenyu; Zheng, Bing; Li, Chancan; Wang, Zaoyu; Bao, Yige; Cai, Ming; Guo, Jianming; Wei, Qiang; Xue, Wei.
Affiliation
  • Huang J; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Su R; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen Z; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Jiang S; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Chen M; Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
  • Yuan Y; Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Hu H; Department of Urology, The second hospital of Tianjin medical university, Tianjin, China.
  • Fu C; Department of Urology, Quanzhou First Hospital affiliated to Fujian Medical University, Quanzhou, China.
  • Huang Z; Department of Urology, Quanzhou First Hospital affiliated to Fujian Medical University, Quanzhou, China.
  • Wang Z; The Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, China.
  • Zheng B; The Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, China.
  • Li C; The Department of Urology, AnHui NO. 2 Provincial People Hospital, Hefei, China.
  • Wang Z; Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Bao Y; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Cai M; Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Guo J; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Wei Q; Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Xue W; Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Oncoimmunology ; 11(1): 2124691, 2022.
Article in En | MEDLINE | ID: mdl-36148322
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Oncoimmunology Year: 2022 Document type: Article Affiliation country: China Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Oncoimmunology Year: 2022 Document type: Article Affiliation country: China Country of publication: United States